Physician profile
Helena Lam
NPI 1821651225
$2,224.73
in general payments reported to CMS, 2019-2025
13 companies · $576 in 2025
The $576 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $73.93 · 2022: $146 · 2023: $425 · 2024: $1,005 · 2025: $576.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,005.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,005.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $989.25 | 2024-2025 | Tepezza |
| Horizon Therapeutics Plc | $310.33 | 2023 | Tepezza |
| Alcon Vision LLC | $145.50 | 2022 | |
| Bausch & Lomb Americas INC. | $137.02 | 2024 | |
| Sun Pharmaceutical Industries INC. | $124.85 | 2025 | |
| Dompe US, INC. | $121.85 | 2024 | Oxervate |
| Stryker Corporation | $90.51 | 2024 | Na |
| New World Medical,INC. | $83.27 | 2023 | |
| Avanir Pharmaceuticals, INC. | $73.93 | 2019 | |
| Abbvie INC. | $50.44 | 2023-2024 | |
| Merz Pharmaceuticals, LLC | $41.39 | 2024 | Xeomin |
| Glaukos Corporation | $39.58 | 2025 | Idosetr |
| Apellis Pharmaceuticals, INC. | $16.81 | 2023 | Syfovre |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Helena Lam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.